Skip NavigationSkip to Content

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera

  1. Author:
    Hickey,Thomas
    Mudunuri,Uma
    Hempel,Heidi
    Kemp,Troy
    Roche,Nancy
    Talsania, Keyur
    Sellers, Brian A
    Cherry, James M
    Pinto,Ligia
  2. Author Address

    Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Center for Human Immunology, Inflammation and Autoimmunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.,
    1. Year: 2025
    2. Date: Jan 27
    3. Epub Date: 2025 01 27
  1. Journal: Frontiers in Immunology
    1. 15
    2. Pages: 1502458
  2. Type of Article: Article
  3. Article Number: 1502458
  1. Abstract:

    The first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination. In this proof-of-concept study, sera from male and female vaccine recipients were evaluated for proteomic and immunologic responses 1-month and 6-months following homologous third vaccination. An aptamer-based (7,289 marker) proteomic assay coupled with traditional serology was leveraged to generate a comprehensive evaluation of systemic responsiveness in 64 and 68 healthy recipients of mRNA-1273 and BNT162b2 vaccines, respectively. Sera from female recipients of mRNA-1273 showed upregulated indicators of inflammatory and immunological responses at 1-month post-third vaccination, and sera from female recipients of BNT162b2 demonstrated upregulated negative regulators of RNA sensors at 1-month. Sera from male recipients of mRNA-1273 showed no significant upregulation of pathways at 1-month post-third vaccination, though there were multiple significantly upregulated proteomic markers. Sera from male recipients of BNT162b2 demonstrated upregulated markers of immune response to doublestranded RNA and cell-cycle G(2)/M transition at 1-month. Random Forest analysis of proteomic data from pre-third-dose sera identified 85 markers used to develop a model predictive of robust or weaker IgG responses and antibody levels to SARS-CoV-2 spike protein at 6-months following boost; no specific markers were individually predictive of 6-month IgG response. Thirty markers that contributed most to the model were associated with complement cascade and activation; IL-17, TNFR pro-apoptotic, and PI3K signaling; and cell cycle progression. These results demonstrate the utility of proteomics to evaluate correlates or predictors of serological responses to SARS-CoV-2 vaccination. Copyright © 2025 Hickey, Mudunuri, Hempel, Kemp, Roche, Talsania, Sellers, Cherry and Pinto.

    See More

External Sources

  1. DOI: 10.3389/fimmu.2024.1502458
  2. PMID: 39931577
  3. PMCID: PMC11808009

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel